Search results

Order by most recent / most popular / relevance

Results: 1-10 of 26

Winners announced in $20k new venture competition for medical device technologies in Massachusetts

Nutter McClennen & Fish LLP
-
USA
-
April 10 2013

Little Sparrows, Cellanyx Diagnostics, and BioSignostix today were named the 2013 winners of the Second Annual M2D2 New Venture Competition awards

Genzyme allowed to proceed with Lanham Act claim against Shire Human Genetic Therapies but not parent company

Nutter McClennen & Fish LLP
-
USA
-
February 15 2013

Plaintiff Genzyme Corp. ("Genzyme") brought this action against Defendants Shire Human Genetic Therapies, Inc. ("Shire HGT") and Shire plc ("Shire"

In major ruling, federal appeals court limits prosecutions for off-label promotion, on constitutional grounds

Nutter McClennen & Fish LLP
-
USA
-
December 4 2012

On December 3, 2012, the Second Circuit Court of Appeals ruled that the Food, Drug and Cosmetic Act cannot be interpreted to prohibit truthful, non-misleading speech about lawful unapproved uses of an FDA-approved drug, because such an interpretation of the law would violate the First Amendment

Federal Circuit reaffirms (again) gene patents in Myriad

Nutter McClennen & Fish LLP
-
USA
-
August 20 2012

On August 16, 2012, biotechnology patent owners breathed a short sigh of relief, as the US Court of Appeals for the Federal Circuit issued the highly anticipated decision in Association for Molecular Pathology v. Myriad Genetics, finding that DNA sequences are indeed eligible for patent protection

Executive compensation at risk: government prosecutors unveil new enforcement method in recent GlaxoSmithKline healthcare fraud settlement

Nutter McClennen & Fish LLP
-
USA
-
August 15 2012

GlaxoSmithKline’s (“GSK”) recent agreement to plead guilty and pay $3 billion to resolve its liability for the unlawful promotion of certain prescription drugs has been touted by the U.S. Justice Department (“DOJ”) as the largest healthcare fraud settlement in history and the largest payment ever by a drug company

Massachusetts FY 2013 Budget contains important sales and marketing changes for pharmaceutical and medical device manufacturers

Nutter McClennen & Fish LLP
-
USA
-
July 27 2012

Effective July 1, 2012, pursuant to provisions in the Massachusetts FY 2013 Appropriations Act (the state budget), pharmaceutical and medical device manufacturers (“Manufacturers”) will now be able to provide or pay for “modest meals and refreshments” for health care practitioners in connection with certain non-CME educational presentations

The US health care law: what’s next for stakeholders

Nutter McClennen & Fish LLP
-
USA
-
July 9 2012

In a widely publicized recent health care ruling, the Supreme Court largely upheld the Patient Protection and Affordable Care Act (ACA

USPTO issues patentability guidelines under Mayo v. Prometheus

Nutter McClennen & Fish LLP
-
USA
-
July 6 2012

On July 5, 2012, the United States Patent and Trademark Office issued a memorandum to all patent examiners providing guidelines for examining process claims for patent eligibility in view of the Supreme Court decision Mayo v. Prometheus

Supreme Court rules on Affordable Care Act

Nutter McClennen & Fish LLP
-
USA
-
June 28 2012

This morning the Supreme Court released its decision regarding the Obama administration’s healthcare reform legislation

The Supreme Court speaks on diagnostic patentsMayo v. Prometheus and Myriad

Nutter McClennen & Fish LLP
-
USA
-
May 22 2012

The Supreme Court issued two long-awaited decisions that are likely to have broad-reaching effects on diagnostic method patents, as well as personalized medicine patents

next >